Patents by Inventor Eric C. Breinlinger

Eric C. Breinlinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20230066771
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: July 23, 2021
    Publication date: March 2, 2023
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20210130293
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: October 16, 2019
    Publication date: May 6, 2021
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING
    Publication number: 20200255423
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Application
    Filed: October 16, 2019
    Publication date: August 13, 2020
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher, Theresa A. Dunstan, David A. Schiedler
  • Inhibitors of tyrosine kinase 2 mediated signaling
    Patent number: 10508113
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: December 17, 2019
    Assignee: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher
  • INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING
    Publication number: 20190276450
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 12, 2019
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher
  • Indazolones as modulators of TNF signaling
    Patent number: 10273238
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 30, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel S. Wilson
  • Tricyclic modulators of TNF signaling
    Patent number: 10266532
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 23, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson, Jerome Daanen, Stevan Djuric, Amanda W. Dombrowski, Arthur Gomtsyan, Robert Schmidt
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20190055196
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: August 22, 2018
    Publication date: February 21, 2019
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • Nuclear receptor modulators
    Patent number: 10106501
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: October 23, 2018
    Assignee: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20180215764
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 2, 2018
    Inventors: Eric C. Breinlinger, Andrew Burchat, Justin D. Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine T. Osuma, Anil Vasudevan, Noel S. Wilson
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20180179198
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 28, 2018
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson
  • Tricyclic modulators of TNF signaling
    Patent number: 9856253
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 2, 2018
    Assignee: AbbVie, Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Anil Vasudevan, Noel Wilson
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20160362370
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 15, 2016
    Applicant: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20160304517
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Eric C. Breinlinger, Phil B. Cox, Jerome Daanen, Justin Dietrich, Stevan Djuric, Amanda W. Dombrowski, Kristine E. Frank, Michael M. Friedman, Arthur Gomtsyan, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Robert Schmidt, Anil Vasudevan, Noel Wilson
  • ISOXAZOLINES AS THERAPEUTIC AGENTS
    Publication number: 20150297596
    Abstract: The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: April 27, 2015
    Publication date: October 22, 2015
    Applicant: ABBVIE INC.
    Inventors: David J. Calderwood, Eric C. Breinlinger, Steven L. Swann, Subhendu Mukherjee, Venkata Srikanth Chitty, Siva Sanjeeva Rao Thunuguntla, Subramanya Seetharama Shastry Hosahalli
  • Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof
    Patent number: 9115151
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: August 25, 2015
    Assignee: AbbVie Inc.
    Inventors: Dawn M. George, Maria A. Argiriadi, Martine Barth, Dominique Bonafoux, Eric C. Breinlinger, Linlin Dai, Jeremy Edmunds, Michael M. Friedman, Fabrice Guillier, Adrian D. Hobson, Dominique Potin, Didier Thomas, Jianfei Wang, Wentao Wu, Yang Zhang
  • Isoxazolines as therapeutic agents
    Patent number: 9029409
    Abstract: The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: David J. Calderwood, Eric C. Breinlinger, Steven L. Swann, Venkata Srikanth Chitty, Subramanya Seetharama Shastry Hosahalli, Subhendu Mukherjee, Siva Sanjeeva Rao Thunuguntla
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20140349970
    Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 9, 2014
    Publication date: November 27, 2014
    Applicant: ABBVIE INC.
    Inventors: Neil Wishart, Maria A. Argiriadi, Eric C. Breinlinger, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael Friedman, Dawn M. George, Eric R. Goedken, Michael Z. Hoemann, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kelly D. Mullen, Gagandeep Somal, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • TRIAZINONE COMPOUNDS
    Publication number: 20140206663
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: March 19, 2014
    Publication date: July 24, 2014
    Inventors: Jianfei Wang, Eric C. Breinlinger, Martine Barth, Michael M. Friedman, Fabrice Guillier, Maria A. Argiriadi, Jeremy Edmunds, Dominique Potin, Adrian D. Hobson, Wentao Wu, Dominique Bonafoux, Didier Thomas, Dawn M. George, Linlin Dai, Yang Zhang
  • Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
    Patent number: 8785639
    Abstract: The invention provides a compound of Formula (Ie), pharmaceutically acceptable salts, or stereoisomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: July 22, 2014
    Assignee: AbbVie Inc.
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Kristine E. Frank, Dawn M. George, Eric R. Goedken, Michael Friedman, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Jeffrey W. Voss, Lu Wang, Eric C. Breinlinger, Kelly D. Mullen, Gagandeep Somal, Michael Z Hoemann